Abstract: The present invention relates to a new process for the production of substituted 2-[2-(phenyl) ethylaminojalkaneamide derivatives of the following formula (I), in particular 2-[2-(3-butoxyphenyl)-ethylamino]-N,N-dimethylacetamide in high yields with very high chemical purity.
Type:
Grant
Filed:
April 8, 2020
Date of Patent:
November 5, 2024
Assignee:
Newron Pharmaceuticals S.p.A.
Inventors:
Wolfgang Skranc, Michael Wolberg, Matthias Riepl, Christoph Imboden, Erwin Waldvogel
Abstract: A method for producing an aqueous equilibrium peroxylactic acid solution by reaction mixing lactic acid, hydrogen peroxide, water, one or more optional acid catalysts and one or more optional sequestering agents in a vessel over a period of time while maintaining the temperature of the solution at a temperature below about 100° C. The aqueous equilibrium peroxylactic acid solution can be used for reducing the bacterial count on food products, particularly a protein food product, during processing.
Type:
Grant
Filed:
March 30, 2021
Date of Patent:
November 5, 2024
Assignee:
Zeco, LLC
Inventors:
Robert C. Bullard, Jonathon R. Bullard, James A. Faller, A. Rider Barnum
Abstract: The present invention relates to an improved process for preparing hydrazine hydrate from the azine of methyl ethyl ketone obtained from methyl ethyl ketone by oxidizing ammonia with hydrogen peroxide in the presence of an activator, characterized in that it comprises a step of recycling the pyrazoline-class heterocycles purge.
Abstract: The invention is directed to Muramyl Dipeptide (MDP) derivative compounds of structural Formula-VIII, a process for synthesis, intermediates used in the synthesis and use thereof: wherein, R can be a linear or branched alkyl, an aryl, a substituted aryl, or an alkoxy alkyl. These compounds possess excellent pharmacological properties, in particular immunomodulating properties for use as adjuvant in vaccine formulations. These compounds are particularly useful as adjuvants in vaccines.
Type:
Grant
Filed:
May 24, 2021
Date of Patent:
November 5, 2024
Assignees:
Bharat Biotech International LTD., Council of Scientific and Industrial Research
Abstract: Aspects of the disclosure includes methods for preparing an amorphous solid composition of a fatty acid metal salt. In practicing the subject methods according to certain embodiments, a succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane organic salt is contacted with a metal base to produce a succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt; and the succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt is precipitated in a solvent to produce an amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition. An amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane lithium salt is also provided.
Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
Type:
Grant
Filed:
December 15, 2023
Date of Patent:
October 22, 2024
Assignee:
Novo Nordisk A/S
Inventors:
Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
Abstract: Provided herein are Complement Factor I (CFI) variants that exhibit at least one improved characteristic relative to a wild type CFI. CFI variants of the disclosure can exhibit tunable specificity and activity. Also included are CFI-containing fusion constructs comprising at least one domain of CFI, for example, wild type full length CFI fused to human serum albumin. Also included are methods of making and using such CFI variants and fusion constructs. The CFI variants and fusion constructs provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system or a deficiency of CFI.
Type:
Grant
Filed:
June 14, 2021
Date of Patent:
October 15, 2024
Assignee:
Vertex Pharmaceuticals Incorporated
Inventors:
Grant E. Blouse, Brajesh Kumar, Tom Knudsen, Jan Kristian Jensen, Emil Oldenburg, Christine René Schar, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way, Agnieszka Jendroszek, Arzu Sandikci, Jim McGuire, Shyam Rajan Iyer, Natacha Le Moan
Abstract: A germinant mixture includes a) a bile acid main germinant, b) an amino acid co-germinant, c) an edible spore solubilizing agent, and d) a divalent metal salt co-germinant. Also described is an oral pharmaceutical composition including the germinant mixture and a pharmaceutically acceptable excipient. A method of treating, decolonizing, and/or preventing C. difficile infection in the gastrointestinal tract of a patient in need thereof includes orally administering the germinant mixture or the oral pharmaceutical composition and an antibiotic that is active against C. difficile to the patient in need thereof.
Abstract: The present disclosure relates to Dopa containing ultrashort peptides capable of forming a gel, to a gel comprising a peptide in accordance with the present disclosure, and to a glue comprising a peptide in accordance with the present disclosure. Such gel is adhesive and is biocompatible. The peptides are suitable for building 3D structures, 3D printing, gluing as well as other applications.
Type:
Grant
Filed:
September 2, 2021
Date of Patent:
October 15, 2024
Assignee:
KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
Inventors:
Charlotte A. E. Hauser, Maria Hountondji, Manola Moretti, Panagiotis Bilalis
Abstract: The present disclosure provides novel polypeptide conjugates. The polypeptide conjugates disclosed herein comprise a stapled peptide comprising a peptide and at least one staple which holds the peptide in an ?-helical conformation, and a cyclic cell-penetrating peptide (cCPP) conjugated, directly or indirectly, to the stapled peptide. The present disclosure demonstrates that cCPPs can be used to confer consistent cell-permeability to stapled peptides.
Abstract: The present disclosure provides a stapled peptide and use thereof in preparation of a drug for treating pancreatic cancer, belonging to the technical field of biomedicine. The stapled peptide is prepared by using a linear peptide with an amino acid sequence shown in SEQ ID NO: 1 as a peptide chain template, and replacing i-th and (i+7)-th amino acids of the linear peptide with S5 separately and conducting cyclization; alternatively, replacing n-th and (n+4)-th amino acids of the linear peptide with S5 separately and conducting cyclization; where S5 is 2-amino-2-methyl-6-heptenoic acid; i is a positive integer of less than or equal to 7, and n is a positive integer of less than or equal to 10. The stapled peptide treats LINC00261-deficient pancreatic cancer, N1DARP-deficient pancreatic cancer, or gemcitabine-resistant pancreatic cancer by specifically inhibiting a deubiquitination activity of USP10.
Type:
Grant
Filed:
December 12, 2022
Date of Patent:
October 15, 2024
Assignee:
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Abstract: The invention provides a method and/or composition for the treatment of bone cancer including primary bone cancer and secondary bone cancer, breast cancer, skin cancer, nasopharyngeal carcinoma, oral cancer, vulva cancer, prostate cancer, cervical cancer, melanoma including melanocarcinoma by percutaneous and/or transmucosal administration of the interferon. Further, the invention provides a method and/or composition for the treatment of skin, subcutaneous, mucosal and/or submucosal primary cancer and cancer metastatic lesions by percutaneous and/or transmucosal administration of the interferon, especially a method and/or composition for the treatment of bone cancer pain including pain resulted by secondary bone cancer.
Abstract: Provided are a divalent phosphazenium salt which is neutral and is excellent in thermal stability and aldehyde scavenging ability, and a method for producing the same. Also provided are a polyalkylene oxide composition having a volatile aldehyde amount reduced, having generation of odor and turbidity suppressed and being excellent in urethanization reactivity, and a method for producing such a polyalkylene oxide composition, as well as a polyurethane-forming composition containing the polyalkylene oxide composition. A divalent phosphazenium salt having a specific structure. Also, a polyalkylene oxide composition comprising a divalent phosphazenium salt having a specific structure and a polyalkylene oxide, a method for producing the same, and a polyurethane-forming composition containing the same.
Type:
Grant
Filed:
March 5, 2019
Date of Patent:
October 8, 2024
Assignee:
TOSOH CORPORATION
Inventors:
Yoshiaki Inoue, Toshihide Yamamoto, Katsuaki Mori
Abstract: The present disclosure provides ACE inhibitory peptide composition derived from ginkgo protein and preparation method and application thereof, belonging to the technical field of food and medicine. The ACE inhibitory peptide composition derived from ginkgo protein mainly consists of six small molecular peptides with amino acid sequences of GFDGR (SEQ ID NO. 1), NDPGR (SEQ ID NO. 2), LDQTYRP (SEQ ID NO. 3), REHETIIL (SEQ ID NO. 4), LRMPGPPSDDY (SEQ ID NO. 5) and LRMPGPPSDDYER (SEQ ID NO. 6). The specific preparation process includes preparation of ginkgo protein, hydrolysis of ginkgo protein, enzymolysis and hydrolysis of ginkgo protein to obtain crude ACE inhibitory peptide, and separation and purification of ACE inhibitory peptide composition derived from ginkgo protein.
Abstract: The present disclosure provides IL12 and IL23 muteins as partial agonists comprising modified human p40 molecules that associate with human p35 (hP35) and human P19 (hP19) to form modified hIL-12 and IL23 partial agonists wherein the individual components of IL12 and IL23 muteins are linked to engineered Fc domains.
Abstract: Process for the preparation of urea granules comprising the steps of obtaining an aqueous urea solution from one or more synthesis and recovery steps wherein ammonia and carbon dioxide are reacted together, subjecting the aqueous urea solution to an evaporation step wherein water is removed to obtain a urea melt (1), processing and treating said urea melt in a granulation step (7) and optionally in a cooling section (10) to obtain solid urea granules (14); the process further comprises a scrubbing step (3) of granulation offgas and an atmospheric evaporation step (32) to recover a urea solution (2) and a water-saturated air stream (18): the water-saturated air stream is fed back to the scrubbing section (3) without condensation, and the recovered urea solution is conveyed to the granulation step (7).
Abstract: Provided is a method for producing a composition containing gallic acid, the composition having a low content rate of protocatechuic acid using a microbial culture solution. A method for producing a composition containing gallic acid, the method comprising a step (A) of performing cooling crystallization using an aqueous solution (a) containing gallic acid and protocatechuic acid at 0.9° C./min or less.
Abstract: Disclosed herein are novel compounds that are Ras inhibitors. Also disclosed are compositions comprising the compounds and methods of using the compounds in treating various diseases.
Type:
Grant
Filed:
July 1, 2020
Date of Patent:
September 24, 2024
Assignee:
Ohio State Innovation Foundation
Inventors:
Roger Briesewitz, Dehua Pei, Punit Upadhyaya
Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
Type:
Grant
Filed:
July 7, 2023
Date of Patent:
September 24, 2024
Assignee:
Novo Nordisk A/S
Inventors:
Andreas Vegge, Daniele Granata, Jais Rose Bjelke, Jacob Lund, Philip Jonas Sassene, Per J. Greisen, Thomas Egebjerg, Evelyn De Tavernier, Soren Steffensen, Marie-Ange Buyse, Frantisek Hubalek, Simone Fulle, Mathias Norrman
Abstract: Disclosed herein is a method for treating cancer in a subject that involves administering to the subject a therapeutically effective amount of a composition comprising a polypeptide that comprises an amino acid sequence corresponding to at the C-terminal SUMO-interacting motif (SIM2) of a DAXX protein. The disclosed polypeptide is not a functional DAXX protein but competes with endogenous DAXX for binding to SUMO.
Type:
Grant
Filed:
September 26, 2023
Date of Patent:
September 17, 2024
Assignee:
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED